Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

Csf1 + AD-MSCs promote stroke repair by activating the resident microglia.

Hou J., Zhang S., Luo S., Zuo X., Ma F., Wang H.

Animal Study on Stroke Research, published in Exp Biol Med (Maywood) (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Exp Biol Med (Maywood) (2025)
Country
Switzerland
Reported sample size
—
Source database
PubMed
PMID
40910104
PMCID
PMC12405005
DOI
10.3389/ebm.2025.10611

Abstract (original English)

The potential of mesenchymal stromal cells (MSCs) in the treatment of hemorrhagic stroke has been demonstrated; however, their clinical efficacy remains inconsistent and further comprehensive studies on their mechanism of action are warranted. In this study, the intracerebral hemorrhage (ICH) rat model was used for intravenous infusion of adipose-derived mesenchymal stromal cells (AD-MSCs) 24 h after modeling. Histopathological techniques and single cell transcriptome sequencing techniques were used to study the mechanism of AD-MSCs promoting the repair of damaged brain tissue. The results indicated that AD-MSCs markedly promote the repair of damaged brain tissues and restored neural function. Single-cell transcriptome sequencing further revealed that this therapeutic effect is specifically through the inhibition of monocyte infiltration in injured brain tissue, promotion of resident microglia proliferation and signaling pathways linked to immune response and neuroprotection. These processes are closely tied to the Csf1 + subgroup of AD-MSCs. For acute hemorrhagic stroke, Csf1 + AD-MSCs promote the repair of damaged brain tissue by activating resident microglia and inhibiting monocyte infiltration. This study offers novel insights into the mechanisms underlying MSC-based stroke treatment and supports the potential for stable and efficacious MSC therapies.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsMicrogliaMesenchymal Stem CellsMesenchymal Stem Cell TransplantationRatsRats, Sprague-DawleyDisease Models, AnimalMacrophage Colony-Stimulating FactorMaleStroke

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research